Status:
RECRUITING
Angiotensin Receptor Blockers in Aortic Stenosis
Lead Sponsor:
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Collaborating Sponsors:
Odense University Hospital
Conditions:
Aortic Stenosis
Aortic Valve Stenosis
Eligibility:
All Genders
20-99 years
Phase:
PHASE4
Brief Summary
This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.
Detailed Description
Studies support the concept that activation of the renin-angiotensin system may be involved in the progression of valve stenosis and myocardial fibrosis in aortic stenosis. Furthermore recent studies ...
Eligibility Criteria
Inclusion
- Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and \<4m/s)
- Normal left ventricular ejection fraction (i.e. ≥50%)
- Systolic blood pressure \>110 mmHg
- Diastolic blood pressure \>70 mmHg
Exclusion
- More than mild aortic or mitral regurgitation, or mitral stenosis
- Current use or documented indication for renin-angiotensin system medication or Aliskiren
- Known allergy or intolerance to angiotensin II receptor blockers (ARBs)
- Alzheimer, dementia or known non-compliant patient
- Renal dysfunction (glomerular filtration rate \<30ml/min/1.73m2)
- Chronic hyperkalemia
- Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment
- Newly diagnosed (\<2 months) or poorly controlled diabetes
- Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (\<3 months)
- Pregnant or lactating women
- Patients unable to read, understand or sign research consent
Key Trial Info
Start Date :
February 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2027
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT04913870
Start Date
February 1 2020
End Date
February 1 2027
Last Update
December 20 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CRIUCPQ
Québec, Quebec, Canada, G1V 4G5
2
Odense University Hospital
Odense, Denmark